News stories about Ionis Pharmaceuticals (NASDAQ:IONS) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.16 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.6620932673576 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- IONS March 2nd Options Begin Trading (nasdaq.com)
- Chairman and CEO of Ionis Pharmaceuticals Inc (NASDAQ:IONS), Crooke Stanley T, sells 10,000 shares worth $520,100 (empowerednews.net)
- Ionis Pharmaceuticals Inc (IONS) Chairman Sells $572,110.00 in Stock (americanbankingnews.com)
- This Is Why Alnylam Pharmaceuticals Soared 249% in 2017 (finance.yahoo.com)
- Monthly Low Performance: Ionis Pharmaceuticals, Inc. (IONS) fluctuated -1.67% – The Stocks News (press release) (thestocksnews.com)
Ionis Pharmaceuticals (IONS) traded down $0.58 during mid-day trading on Thursday, reaching $53.17. The company had a trading volume of 759,742 shares, compared to its average volume of 898,009. The stock has a market capitalization of $6,610.00, a PE ratio of 379.79 and a beta of 2.86. Ionis Pharmaceuticals has a 12-month low of $37.26 and a 12-month high of $65.51. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25.
In related news, Chairman Stanley T. Crooke sold 11,000 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $52.01, for a total transaction of $572,110.00. Following the completion of the sale, the chairman now owns 48,014 shares in the company, valued at $2,497,208.14. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 16,500 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The stock was sold at an average price of $59.46, for a total value of $981,090.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,549 shares of company stock valued at $7,210,500. 2.13% of the stock is owned by company insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.